entertainment -WSS

entertainment

author：explore 2025-10-01 12:36:05 - browse：7

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Will the IRA bring competition to the biologics market?

entertainment

WSS

White House touts steps to stem shortages of cancer treatments

Popular nasal decongestant doesn't actually relieve congestion

How to make the FDA’s new prescription one

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Clinical trials must include more disabled people

How medical schools plan to diversify without affirmative action

hotspot

entertainment

Wikipedia

What does generative AI mean for health care? We asked experts

Hilary expected to bring catastrophic, life

Medical records are filled with copy

Patient advocates sound warning on FDA proposal on salt intake

United colonoscopy coverage change 'may cost lives,' doctors say

Clinical trials must include more disabled people

Novavax promises a turnaround & Lilly roils the obesity market

An interview with Robert F. Kennedy Jr. on vaccines

How to save PrEP access — and even expand it

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

New details revealed about Purdue's marketing of OxyContin

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Will the IRA bring competition to the biologics market?

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Hilary expected to bring catastrophic, life

Diverse clinical trials: Why aren’t we there yet?

leisure time

entertainment

knowledge

Wikipedia